Trials / Unknown
UnknownNCT01872936
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Santaris Pharma A/S · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label study is to assess the safety, tolerability, antiviral activity, genotype resistance associated with virological failure, pharmacokinetics and pharmacodynamics of two dose regimens of miravirsen in combination with telaprevir and ribavirin in subjects with hepatitis C virus genotype 1 infection who are null responder to pegylated-interferon alpha and ribavirin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Miravirsen | |
| DRUG | Telaprevir | |
| DRUG | Ribavirin |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2013-06-07
- Last updated
- 2014-11-18
Locations
3 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01872936. Inclusion in this directory is not an endorsement.